SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Anticipation of HLP003s pivotal Phase 3 APPROACH readout is driving attention after enrollment was completed ahead of schedule, keeping topline data on track for Q4 2026. Traders are largely bullish on the program, reinforced by the new CEO and reported insider buying, while others warn that dilution, profit-taking, and binary clinical risk could increase volatility.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

A Ninth Circuit ruling that states can regulate or ban sports event contracts is driving attention, with traders viewing the setback for Kalshi and other prediction markets as a potential competitive win for DraftKings ahead of football season. Debate remains over whether the decision ultimately helps DraftKings, which is also expanding its own prediction-market business, as further appeals and regulatory uncertainty persist.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

FDA approval of FAYUVI, the first approved treatment for Sanfilippo syndrome Type A, along with a Priority Review Voucher, is driving attention around Ultragenyx. Traders are broadly bullish on the new commercial asset and potential short covering, while skeptics cite the limited patient population, treatment risks, commercialization challenges, and ongoing cash burn to explain the relatively muted reaction.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

The Federal Reserves rate hike and signal that further tightening may follow have driven attention to IWM, with traders highlighting higher yields and small caps rate sensitivity as pressure on the Russell 2000. The community is largely bearish amid technical weakness and put activity, though some traders argue the move is oversold and anticipate a relief bounce.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

Dutch Bros is drawing attention after a sharp selloff tied to the failed or contested Salad and Go acquisition, alongside concerns that its growth-stock valuation is too high amid weaker consumer spending, elevated rates, and competition. Traders are split between viewing the decline as an oversold buying opportunity supported by continued store expansion and seeing further downside from slowing growth, potential dilution, and heavy short interest.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckins expanded share-repurchase program is the dominant catalyst, with traders viewing the buybacks as evidence of undervaluation and a potential reduction in the float. Others argue the program is masking selling by Centurium and keeping the OTC stock range-bound, while speculation about a future relisting adds to the debate.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Barclays bullish analyst action, citing Lifileucels durability and the upcoming IOV-LUN-202 lung-cancer update, has amplified attention alongside expectations for revised guidance and continued Amtagvi commercial growth. Traders are broadly bullish and discuss short covering, while others attribute the sharp move to profit-taking and options-driven volatility ahead of those catalysts.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEARs rally is being linked by traders to Zcashs strength, with speculation that capital is rotating between the two tokens and that NEAR could catch up after lagging. Sentiment is broadly bullish, though some traders caution that the move may be a short-term pump facing technical resistance and potential pullback.

Verizon Communications, Inc. is a holding company, which engages in the provision of communications, information, and entertainment products and services. It operates through the following business segments: Consumer and Business. The Consumer segment provides consumer-focused wireless and wire line communications services and products. The Business segment offers wireless and wireline communications services and products, including FWA broadband, data, video and conferencing services, corporate networking solutions, security and managed network services, local and long-distance voice services, and network access to deliver various IoT services and products. The company was founded in 1983 and is headquartered in New York, NY.

Verizon Communications Inc

Verizon Communications Inc.

SpaceXs plans to expand Starlink into a full mobile network are driving attention, with traders debating whether the satellite-terrestrial service could pressure Verizons wireless and broadband growth. Bullish participants argue Verizons existing fiber infrastructure, AI-related connectivity deals, subscriber gains and dividend make the selloff an overreaction, while bears cite competitive and debt risks.

Forgent Power Solutions, Inc. is a holding company, which engages in the design and manufacture of electrical distribution equipment used in data centers, power grid, and energy-intensive industrial facilities. It also offers powertrain solutions and standard and custom products. The company was founded on July 21, 2025 and is headquartered in Dayton, MN.

Forgent Power Solutions Inc. - Ordinary Shares - Class A

Forgent Power Solutions Inc.

Strong fiscal fourth-quarter results, above-consensus FY27 guidance, record orders and a large firm backlog are driving attention, reinforcing the thesis that Forgent benefits from AI data-center and power-infrastructure demand. Traders are broadly bullish on the growth outlook, though some remain concerned about the Neos share overhang, dilution risk and the stocks sharp prior correction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$AAPL Red arrow shows alternate in event correction is an expanded flat and we tank on quadruple witching Friday.

Memo

Stocktwits

Apple Inc

 Red arrow shows alternate in event correction is an expanded flat and we tank on quadruple witching Friday.